Sage Therapeutics Inc (SAGE)
11.70
-0.31
(-2.58%)
USD |
NASDAQ |
May 17, 16:00
11.70
0.00 (0.00%)
After-Hours: 20:00
Sage Therapeutics Cash from Financing (Quarterly): 1.557M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.557M |
| December 31, 2023 | -0.262M |
| September 30, 2023 | 2.77M |
| June 30, 2023 | 0.847M |
| March 31, 2023 | 2.672M |
| December 31, 2022 | 0.029M |
| September 30, 2022 | 1.229M |
| June 30, 2022 | 0.013M |
| March 31, 2022 | 1.799M |
| December 31, 2021 | -0.17M |
| September 30, 2021 | 1.816M |
| June 30, 2021 | 6.065M |
| March 31, 2021 | 5.623M |
| December 31, 2020 | 419.67M |
| September 30, 2020 | 3.545M |
| June 30, 2020 | 0.386M |
| March 31, 2020 | 3.16M |
| December 31, 2019 | 2.166M |
| September 30, 2019 | 13.92M |
| June 30, 2019 | 15.34M |
| March 31, 2019 | 576.20M |
| December 31, 2018 | 1.628M |
| September 30, 2018 | 8.078M |
| Date | Value |
|---|---|
| June 30, 2018 | 6.54M |
| March 31, 2018 | 643.11M |
| December 31, 2017 | 334.82M |
| September 30, 2017 | 3.687M |
| June 30, 2017 | 2.758M |
| March 31, 2017 | 0.553M |
| December 31, 2016 | 0.678M |
| September 30, 2016 | 189.59M |
| June 30, 2016 | 0.01M |
| March 31, 2016 | 140.70M |
| December 31, 2015 | 0.031M |
| September 30, 2015 | 0.137M |
| June 30, 2015 | 129.59M |
| March 31, 2015 | 0.112M |
| December 31, 2014 | -0.249M |
| September 30, 2014 | 95.16M |
| June 30, 2014 | -1.023M |
| March 31, 2014 | 52.98M |
| December 31, 2013 | 0.261M |
| September 30, 2013 | 17.49M |
| June 30, 2013 | 0.03M |
| March 31, 2013 | 5.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.262M
Minimum
Dec 2023
419.67M
Maximum
Dec 2020
24.11M
Average
1.991M
Median
Cash from Financing (Quarterly) Benchmarks
| Biogen Inc | -439.60M |
| Vanda Pharmaceuticals Inc | -- |
| Ligand Pharmaceuticals Inc | 12.18M |
| ADMA Biologics Inc | -1.447M |
| Axsome Therapeutics Inc | -1.187M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -37.83M |
| Cash from Investing (Quarterly) | 139.44M |
| Free Cash Flow | -424.74M |
| Free Cash Flow Per Share (Quarterly) | -0.6291 |
| Free Cash Flow to Equity (Quarterly) | -37.83M |
| Free Cash Flow Yield | -60.55% |